Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Polycystic Ovary Syndrome 7Breast Neoplasms 4Peripheral Nervous System Diseases 2Squamous Cell Carcinoma of Head and Neck 1Radiodermatitis 1Primary Ovarian Insufficiency 1Ototoxicity 1Neurotoxicity Syndromes 1Nervous System Diseases 1Mucositis 1Insulin Resistance 1Infertility, Female 1Infertility 1Hyperandrogenism 1Head and Neck Neoplasms 1Disease Progression 1Cisplatin Nephrotoxicity 1Carcinoma, Non-Small-Cell Lung 1Breast Cancer Female 1

Interventions

Paclitaxel 7Oxaliplatin 6Vincristine 4Radiotherapy 4Leucovorin 4Carboplatin 4Amifostine 4Taxes 3Sodium Chloride 3Procarbazine 3Methotrexate 3Fluorouracil 3Cytarabine 3xaliproden 2glucarpidase 2Rituximab 2Radiotherapy, Intensity-Modulated 2Radiotherapy, Conformal 2Prednisolone 2Magnesium Sulfate 2Duloxetine Hydrochloride 2Dexamethasone 2Cyclophosphamide 2Cisplatin 2Calcium Gluconate 2Acupuncture Therapy 2neurotropin 1motexafin gadolinium 1haloperidol decanoate 1glutamic acid diethyl ester 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neurotoxicity Syndromes × Thioctic Acid × Clear all
NCT00112996 2014-04-08

Alpha-Lipoic Acid in Preventing Peripheral Neuropathy in Patients Receiving Chemotherapy for Cancer

M.D. Anderson Cancer Center

Phase 3 Completed
244 enrolled

Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡